logo-loader
Netscientific PLC

ProAxsis boss “excited by the potential” of protease detection technology

David Ribeiro, chief executive of ProAxsis , a portfolio company of Netscientific PLC (LON:NSCI) has high hopes for its protease detection, which measures levels of neutrophil elastase, released in sufferers of chronic respiratory disease.

He hopes to develop a monitoring system to track the levels of neutrophil elastase to long term chronic decline in lung function in those afflicted with cystic fibrosis and COPD (chronic obstructive pulmonary disease).

“We’re trying to monitor the disease and get an early warning of when the person is going to get worse by measuring their elastase,” he explains.

“What we’d really like to do is create a simple point of care test the patient can use at a clinic or at home to track elastase levels long term.”

The group is hoping to have the test available early as 2017.

“I am genuinely excited by the challenges I’ve had in the last six months and I’m very excited by the potential for the work that we’re doing,” says Ribeiro.

Quick facts: Netscientific PLC

Price: £0.07

Market: AIM
Market Cap: £5.3 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Netscientific PLC named herein, including the promotion by the Company of Netscientific PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: ANGLE reports positive data from Parsortix FDA clinical study

Top stories from the Proactive Investors UK newsroom: ANGLE PLC (LON:AGL) has received positive results from its Parsortix FDA clinical study for metastatic breast cancer. The 400-subject clinical study will support an application for Class II regulatory clearance for Parsortix in the...

on 31/5/19

2 min read